AMENDMENT NO. 1 TO THE PHASE IB/II COMBINATION STUDY AGREEMENTPhase Ib/Ii Combination Study Agreement • March 9th, 2020 • Corvus Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS AMENDMENT NO. 1 TO THE PHASE IB/II COMBINATION STUDY AGREEMENT (this “Amendment”) dated as of December 20, 2017 amends the Phase IB/II Combination Study Agreement (the “Agreement”), made and entered into as of May 1, 2017, between Corvus Pharmaceuticals, Inc., having a principal office located at 863 Mitten Road, Suite 102, Burlingame, CA 94010 (“Corvus”), and Genentech, Inc., having a principal office located at 1 DNA Way, South San Francisco, CA 94080.
PHASE IB/II COMBINATION STUDY AGREEMENT BETWEEN GENENTECH, INC. AND CORVUS PHARMACEUTICALS, INC.Phase Ib/Ii Combination Study Agreement • August 3rd, 2017 • Corvus Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS PHASE IB/II COMBINATION STUDY AGREEMENT (“Agreement”) is made and entered into, effective as of May 1, 2017 (“Effective Date”), by and between Genentech, Inc., a Delaware corporation, having a principal place of business at 1 DNA Way, South San Francisco, California 94080 (“Genentech”) and Corvus Pharmaceuticals, Inc., a Delaware corporation, having a principal place of business at 863 Mitten Road, Suite 102, Burlingame, CA 94010 (“Corvus”). Genentech and Corvus are each referred to herein individually as a “Party” and collectively as the “Parties.”
